Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib

Ähnliche Einträge

• A two-fold rise of BCR-ABL transcript levels advises BCR-ABL mutation analysis in imatinib-treated chronic myeloid leukemia (CML): an analysis of the randomized CML-study IV
  Veröffentlicht: (2014)
• Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
  Veröffentlicht: (2014)
• Comparing the prognostic significance of early predictors of survival in chronic myeloid leukemia (CML) treated with imatinib: an analysis of the randomized CML-study IV
  Veröffentlicht: (2014)
• Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center
  von: Lahaye, Tanja, et al.
  Veröffentlicht: (2005)
• BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?
  von: Neuendorff, Nina Rosa, et al.
  Veröffentlicht: (2018)